Products
News
Resources
Contact
Language
简体中文
繁體中文
English
日本語
한국어
Tiếng Việt
Overview
Latest
Regional
Industry
Featured
Multimedia
Other Languages
Public Company News
All
APAC
Global
All
APAC
Global
All
APAC
Global
All
APAC
Global
{{toptitleLeft}}
{{toptitleRight}}
{{selectTitle}}
{{toptitleLeft}}
{{index}}
{{select_list_per.name}}
Time
{{showName}}
{{weixin_name}}
X
{{listname}}
Loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.headline}}
{{storydata.create_time}}
{{storydata.headline}}
{{storydata.create_time}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
loading
The End
Network Errors Please Retry
loading
Network Errors Please Retry
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
{{storydata.story.headline}}
{{storydata.story.date_time}}
{{storydata.story.click_num}}
{{theme.pcom_theme_name}}
loading
The End
Network Errors Please Retry
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023
2023-12-15 21:00
Ucommune Regains Compliance with Nasdaq Minimum Bid Price Requirement
2023-12-15 19:30
ZKH Group Limited Announces Pricing of Initial Public Offering
2023-12-15 18:00
Appotronics ALPD® cinema laser light source highlight CineAsia 2023
2023-12-15 16:30
Live from ASH 2023 | Oral Report Featuring Encouraging Data of Olverembatinib Combined with Reduced-Intensity Chemotherapy in Patients with Ph+ ALL Presented at the ASH Annual Meeting
2023-12-15 11:14
Nona Biosciences Enters into a Global License Agreement with Pfizer for HBM9033, an MSLN-Targeted Antibody-Drug Conjugate (ADC)
2023-12-15 07:30
Lunit to Acquire Volpara: Scheme Implementation Agreement Signed
2023-12-14 22:05
China Jo-Jo Drugstores Granted A Second Extension to Meet Nasdaq Minimum Bid Price Requirement
2023-12-14 21:30
CLPS Incorporation Expands Overseas Credit Card Business with the Acquisition of Purple Potato Finance
2023-12-14 21:30
Fibocom Propels Digitalization of Smart Industry Terminals with Customized PCBA Solutions
2023-12-14 21:00
ZK International Group Co., Ltd. Celebrates Prestigious Recognition as a National "Little Giant Enterprise"
2023-12-14 21:00
Joining Hands Towards a Shared Future----Signing Ceremony of Strategic Cooperation Between Ucommune and New World Development (Wuhan) Limited & Forum on Optimizing Building Economy and Collaborating for Breakthrough Development Successfully Held
2023-12-14 19:30
Yunji Announces Third Quarter 2023 Unaudited Financial Results
2023-12-14 19:00
Fosun Pharma's Global Multi-Center Phase III Clinical Trial Project for A New Antimalarial Drug Receives 500 Million Japanese Yen Investment from GHIT Fund to Jointly Improve the Global Accessibility of Antimalarial Drugs
2023-12-14 17:00
Wondershare Virbo Unveils AI-Powered Video Translator: Bridging Language Divides with Innovation
2023-12-14 16:28
51Talk Online Education Group to Report Third Quarter 2023 Financial Results on Monday, December 18, 2023
2023-12-14 16:00
COP28 Highlight: NaaS held "Enterprise-Association-Academy-Research" Hybrid Forum for Seeking Opportunity of China-UAE Cooperation in New Energy
2023-12-14 14:58
JinkoSolar awarded ESG Transparency Award from EUPD Research
2023-12-14 13:58
NaaS Technology Listed in Solactive Electric Vehicle Charging Infrastructure Index
2023-12-14 09:45
Abbisko Therapeutics Announces that U.S. FDA Has Granted Fast Track Designation for Its CSF-1R Inhibitor Pimicotinib (ABSK021)
2023-12-14 08:30
1
345
346
347
348
349
2429